Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.050
+0.089 (9.22%)
At close: Dec 5, 2025, 4:00 PM EST
1.000
-0.050 (-4.76%)
After-hours: Dec 5, 2025, 7:58 PM EST
Cardiol Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | 0.08 | - | |
| Gross Profit | - | - | - | - | 0.08 | - | |
| Selling, General & Admin | 20.77 | 26.26 | 15.56 | 22.37 | 27.87 | 10.09 | |
| Research & Development | 15.5 | 14.01 | 14.22 | 18.96 | 10.87 | 10.6 | |
| Operating Expenses | 36.27 | 40.28 | 29.79 | 41.34 | 38.74 | 20.69 | |
| Operating Income | -36.27 | -40.28 | -29.79 | -41.34 | -38.66 | -20.69 | |
| Interest & Investment Income | 0.86 | 1.19 | 2.04 | 1.24 | 0.11 | 0.08 | |
| Currency Exchange Gain (Loss) | 0.63 | 2.14 | -0.71 | 2.76 | 1.89 | -0.03 | |
| Other Non Operating Income (Expenses) | 0 | 0.27 | 0.33 | 6.41 | 5.03 | 0.01 | |
| Pretax Income | -34.78 | -36.68 | -28.13 | -30.93 | -31.64 | -20.64 | |
| Net Income | -34.78 | -36.68 | -28.13 | -30.93 | -31.64 | -20.64 | |
| Net Income to Common | -34.78 | -36.68 | -28.13 | -30.93 | -31.64 | -20.64 | |
| Shares Outstanding (Basic) | 83 | 72 | 64 | 63 | 43 | 30 | |
| Shares Outstanding (Diluted) | 83 | 72 | 64 | 63 | 43 | 30 | |
| Shares Change (YoY) | 21.91% | 11.02% | 3.13% | 44.61% | 44.77% | 15.63% | |
| EPS (Basic) | -0.42 | -0.51 | -0.44 | -0.49 | -0.73 | -0.69 | |
| EPS (Diluted) | -0.42 | -0.51 | -0.44 | -0.49 | -0.73 | -0.69 | |
| Free Cash Flow | -24.25 | -25.08 | -25.24 | -27.3 | -23.55 | -9.17 | |
| Free Cash Flow Per Share | -0.29 | -0.35 | -0.39 | -0.44 | -0.55 | -0.31 | |
| Gross Margin | - | - | - | - | 100.00% | - | |
| Operating Margin | - | - | - | - | -49091.93% | - | |
| Profit Margin | - | - | - | - | -40170.45% | - | |
| Free Cash Flow Margin | - | - | - | - | -29904.22% | - | |
| EBITDA | -36.41 | -40.11 | -29.59 | -41.16 | -38.44 | -20.46 | |
| D&A For EBITDA | -0.13 | 0.16 | 0.2 | 0.18 | 0.22 | 0.23 | |
| EBIT | -36.27 | -40.28 | -29.79 | -41.34 | -38.66 | -20.69 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.